ANOVA Stem Cell based Treatment for Parkinson's Disease
Parkinson’s Disease (PD) affects millions of people worldwide. The disease is characterized by a slow and progressive deterioration of nerve cells (neurons). It is caused by the death of dopamine-producing neurons in the brain. All currently available medications for Parkinson's are limited to medicating the symptoms only.
Parkinson’s stem cells treatment have demonstrated the ability to stimulate repair and regenerate damaged neurons. ANOVA's Stem Cell Secretome Therapy is the latest development from current stem cell research, allowing for an emerging treatment option that with an immense potential to slow down the disease's progression at different stages.
Parkinson's Diesease: A chronic neurodegenerative disease that is handled with symptom-masking medications only
Parkinson’s Disease is a chronic neurodegenerative disorder caused by selective and gradual loss of dopamine-producing neurons. These neurons are spread throughout the brain, however, the most effected region is the “substantia nigra”. The symptoms of Parkinson's Disease are mainly tremor and rigor. At later stages the illness is characterized by more severe symptoms like speech disorder, depression or even dementia. Currently, there is no cure for Parkinson’s disease.
Nevertheless, there are few hormone replacement-based therapies which tackle the symptoms only. These pharmacological treatments are effective to control the symptoms of PD to a certain degree, with side effects, but are unable to stop neural degeneration, let alone replace dead dopaminergic cells.
Parkinson’s Disease Therapy with Stem Cells:
How can stem cells help?
Diverse stem cell types are under scientific investigations, some of which are in clinical trials, for the safety and efficacy of stem cell-based therapies for treating Parkinson’s disease. They include:
- Dopamine-producing Embryonic Stem Cells (ESCs) for Parkinson’s disease
- Induced pluripotent stem cells (i.e. iPS or iPSCs) for Parkinson’s disease
- Neural stem cells for Parkinson’s disease
- Bone Marrow Concentrate (BMC) for Parkinson’s disease
- Stromal Vascular Fraction (SVF) for Parkinson’s disease
- Lab-grown Mesenchymal Stem Cells (MSCs) for Parkinson’s disease
Modern stem cell research conducted with animals, mainly rats and mice, provided encouraging results in treating PD, bringing regenerative medicine a step closer to finding the cure. Looking at the science of therapies that are based on BMC, SVF and MSCs, in more detail, showed that they were not able to exert their regenerative effects in stimulating the birth of millions of new functioning neurons, from the limited stem cell pool found in the body. Ideally, this is what one could hope for, in order to cure PD.
Nevertheless, some stem cells appear to be able to migrate into the brain and unfold their regenerative effects, which is a promising feature and can help develop an effective treatment for PD. These cells are recruited via paracrine signalling by extracellular vesicles (messaging products) that stem cells secrete in order to communicate with their surroundings. Consequently, the production and release of neurotrophic (stimulating growth of nervous tissue) factors is what ultimately induces these regenerative effects. The so-called Stem Cell Secretome mainly consists of the sum of these released factors (exosomes, microvesicles, growth factors, etc.) that possess the regenerative powers of stem cells.
Stem cell research for Parkinson’s Disease:
What can we do today?
The ANOVA Stem Cell Secretome Therapy for Parkinson’s disease uses Mesenchymal Stem Cells (MSCs). Clinical trials which employ MSCs to treat PD patients have so far shown encouraging results.
MSCs have been shown to secrete many trophic (e.g. prostaglandin E2, TGF-β1, HGF, SDF-1α, indoleamine-2,3-dioxygenase, IL-4, IL-6 and IL-10, SCF, LIF, FGF-2, VEGF, IL-6, EGF, VEGF, Neurotrophin-3 (NT3), SDF-1α, and BDNF) and neuroprotective factors (e.g. NGF, GDNF and BDNF).
The microRNAs (miR-29a, miR-9, miR-124, miR-145) secreted from MSCs' exosomes were also found to promote the differentiation of stem cells into neural cells. In addition to this broad spectrum of neurotrophic and repair inducing factors, exposure of neurons and astrocytes to MSC extracted exosomes leads to an increase of miR-133b. This process promotes the functional recovery of neurons in PD and Spinal Cord Injury.
ANOVA's Stem Cell Secretome is an uniquely designed method, produced specifically to harness and highly concentrate the essence of these bioactive factors, for your personalized treatment. The Secretome, likewise, is produced in full accordance with state of the art methods and German quality controls to ensure the highest product quality and safety for our patients.
We are convinced by scientific data that our method is a promising, effective and much safer treatment than direct injection of MSCs. One of the most important factors of why our method is safe is due to the fact that it relies on growing autologous (from the same patient) fat-derived mesenchymal stem cells (MSC) in a sterile laboratory setting.
New therapeutic approaches that are not solely based on symptomatic reduction, such as the increase of the autophagy process by kinase inhibitors (that are currently undergoing clinical trials) are also considered at ANOVA. They can be included when we design the treatment plan of each individual patient.
If you have any questions, with regards to our stem cell-based treatments and Parkinson's disease or the cost of treatment, then please feel free to contact us by clicking here.
Frequently Asked Questions for Stem Cell treatment of Parkinson's disease
Currently not. However, stem cells already hold a great potential for treating most neurodegenerative diseases, especially Parkinson’s Disease, to slow down or prevent the progression of the disease. This makes it worthwhile for patients and medical professionals alike to consider stem cell-based therapies for specific cases. Each case must be evaluated individually to ensure that the benefits outweigh the risks. In general, it can be said that for cell-based therapeutics which act on a transmitter and paracrine (inter-cell communication) level, the individual success is currently not possible to be predicted. We therefore recommend that you contact us to get an expert opinion on your case and the possibilities we can offer.
The treatment of Parkinson’s Disease with any stem cell method is independent of the stage. Stem cells secrete many healing factors, which can potentially induce a “flourishing” effect on local resident (stem) cells, as well as anti-inflammatory effects wherever they are deployed. This has very positive effects on PD at all stages. However, anticipated results may vary are depending on the progression the treatment plan and the side medications. Contact us for a consultation.
Novel treatments are generally not widely accepted, taught or even mentioned in medical text books or medical training events. The odds are that most doctors never heard of such treatments until sufficient clinical and scientific evidence has been accumulated in form of clinical trials. This process, while necessary, is associated with very high costs, which is why not all clinics can undergo the necessary clinical trials. We at ANOVA are invested in following the scientific progress, especially regarding its safety and efficacy, to offer this treatment option to our patients.
There is no therapy, be it an experimental or established treatment, for which your treating physician can promise or even guarantee a therapeutic success. In the case of innovative and experimental therapies such as stem cell therapy, doctors must perform a benefit-to-risk-analysis for each individual case and ensure that the therapy is beneficial to the patient and these benefits outweigh the risks. Only when this is the case, your doctor will suggest treatment with stem cells.
The underlying cause for the death of nerve cells in the brain are unknown. Several factors are known to play a role:
• Genes: Specific gene mutations were shown to increase the risk for PD
• Environment: Exposure to certain toxins may increase PD risk.
• Age: Usually the age of 60 is the age where PD is most prone to happen
• Sex: Men are more likely to develop PD
Occurring changes in PD changes may be related to Lewy bodies and the Alpha-Synuclein (SNCA) that is contained within these Lewy bodies
Early symptoms and possible warning signs of Parkinson’s disease (PD) are:
• Writing becomes difficult and font is getting involuntarily smaller
• One sided tremor or shaking
• Involuntarily index finger and thumb rolling
• Dizziness or fainting
• Change of facial expression known as mask face
• Soft or lower voice then usual
• Sleep problems usually accompanied with sudden movements
• Walking and otherwise subconscious movements only seem possible when actively imitating them
• Hunching over or stooping
Early symptoms of Parkinson’s disease often go unnoticed. Often one-sided symptoms are first to give indications, as listed below. When noted, a proper diagnose by neurologist needs to be made, as all symptoms can have other causes too:
- Writing changes towards the end of words and sentences
- Balance and posture problems
- Tremor usually starting with the hand at rest or in the thumb and forefingers rolling against each other
- Slowed movements
- Rigid and stiff muscles
- Speech changes
- Decreased ability to do unconscious movements
Parkinson Stage 1: Only mild symptoms occur in facial expressions or slight tremor. However, the daily life is only minimally affected and only one sided.
Parkinson Stage 2: At this stage symptoms are getting worse and affect both sides. The tremor and waling problems are getting worse. Often this is the stage where L-Dopamine is employed.
Parkinson Stage 3: Loss of balance and slowed movements characterize this stage. Living independently is still possible but symptoms significantly impair daily activities.
Parkinson Stage 4: The Symptoms are severely limiting every activity, especially walking. Movements are still possible but may require aid. Usually living alone is not possible at this stage any more.
Parkinson Stage 5: The final and most debilitating stage, where stiffness in legs makes movement impossible. The person requires full time nursing and is bound to the wheelchair. Usually many non-motoric symptoms set like delusions, hallucinations and depressions.
The disease itself is not fatal. However, related complications and symptoms can reduce the life expectancy. A study from the UK found that the life expectancy is between 3-5 years shorter than the average, when the onset of PD is at an age of 65 or older.
It is potentially an option, but it depends on other health factors. The Stem Cell Secretome therapy can be a treatment option for PD and can be employed in combination with other established or new treatments. We recommend that you contact us to get an expert opinion on this subject.
- Riecke J. et al. "A Meta-Analysis of Mesenchymal Stem Cells in Animal Models of Parkinson's Disease." Stem cells and development 24.18 (2015): 2082-2090.
- Ahmed HH. et al. "Updates in the pathophysiological mechanisms of Parkinson’s disease: Emerging role of bone marrow mesenchymal stem cells." World journal of stem cells 8.3 (2016): 106.
- Equbal Z. and Mukhopadhyay A. "Counting on Mesenchymal Stem Cells: A Hope for Treating Parkinson’s Disease. J Stem Cells Res." Rev & Rep 3.1 (2016): 1022.
- Wei X. et al. "Mesenchymal stem cells: a new trend for cell therapy." Acta Pharmacologica Sinica 34.6 (2013): 747-754.
- Wang S. et al. "Clinical applications of mesenchymal stem cells." Journal of hematology & oncology 5.1 (2012): 19.
- Gu W. et al. "Transplantation of bone marrow mesenchymal stem cells reduces lesion volume and induces axonal regrowth of injured spinal cord." Neuropathology 30.3 (2010): 205-217.
- Wilkins A. et al. "Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro." Stem cell research 3.1 (2009): 63-70.